Navigation Links
Pearl Therapeutics' Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva® and Foradil® in Patients with COPD
Date:5/18/2011

or many patients.  I am especially optimistic that PT003 has the potential of fulfilling this unmet need for COPD patients at all stages of severity."

Expanding the benefits beyond its primary endpoint, PT003 also demonstrated a statistically significant improvement in peak FEV1 on day one, with further benefit observed on day seven relative to all comparators and placebo. Treatment with PT003 yielded an improvement in peak FEV1 levels of 42% (or 64 mL) over Foradil and 74% (or 92 mL) over Spiriva as measured on day one; and an improvement of 37% (or 89 mL) over Foradil and 75% (or 141 mL) over Spiriva when measured on day seven (p<0.03 for all comparisons). Furthermore, PT003 demonstrated a faster onset of action than did Spiriva on day one (75% higher probability of onset at any time point during the first 2 hours following administration, p</=0.0003).

PT003 also demonstrated a significant improvement in morning trough FEV1, which is a measure of lung function in patients before they receive their first dose of medication in the morning. This is a particularly relevant measurement for COPD patients who often report that their symptoms are most severe in the morning and cause them to struggle with morning activities. In this Phase 2b study, following one week of study medication, morning trough FEV1 levels in the PT003 arm were improved by 48% (or 68 mL) over Foradil and 52% (or 73 mL) over Spiriva (p<0.014 for both measures).

"The overall improvement in lung function, including the fast onset of action with higher peak improvements in FEV1 and morning trough FEV1 is a strong indicator of how PT003's twice-a-day dosing can benefit patients' disease management," continued Dr. Reisner. "To assess the full clinical potential of PT003, and ensure that we have the strongest possible regulatory package, we plan to initiate four additional Phase 2b studies in the next few weeks. These studies will further
'/>"/>

SOURCE Pearl Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Asante Solutions Receives FDA Clearance for Pearl™ Insulin Pump
2. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
3. Pearl Therapeutics to Present Complete PT003 Results from Phase 2b COPD Study in a Late-Breaker Session at the American Thoracic Society Annual Meeting
4. Asante Solutions, Inc. Receives CE Mark for Pearl™ Insulin Pump
5. Translational Science Expert, Dr. Melissa Ashlock, Joins aTyr Pharma to Advance Physiocrine-based Therapeutics
6. Regency Therapeutics and Daiichi Sankyo Announce Launch and Commercial Availability of SPRIX® (ketorolac tromethamine) Nasal Spray
7. Inhibikase Therapeutics Elects Steven C. Gilman, Ph.D., to Board of Directors
8. Echo Therapeutics Appoints Christopher P. Schnittker as Chief Financial Officer
9. Healthpoint Biotherapeutics Introduces OASIS® Ultra Tri-Layer Matrix
10. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
11. Orexigen® Therapeutics Reports First Quarter Ended March 31, 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 26, 2015 Research and Markets( http://www.researchandmarkets.com/research/nt9zlx/asia_pacific ) ... Mammography Market - Growth, Trends And Forecasts (2014 - ... Mammography is a detailed type of imaging that customs ... exam, called a mammogram, is used to support in ... women. An x-ray (radiograph) is a noninvasive medical test ...
(Date:5/27/2015)... Donatelli, a senior marketing associate with the animal health division of Eli ... a healthcare setting in Bangkok, Thailand , will be ... need with respect and dignity is the guiding star for me and ... in a LillyPad blog . Donatelli and Lilly colleagues ... Colombia , France , Ukraine ...
(Date:5/27/2015)... May 25, 2015 Research and Markets ... addition of the "2015 Strategies in the ... offering. This comprehensive five-country report contains ... help current suppliers and potential market entrants identify ... coagulation testing market during the next five years. ...
Breaking Medicine Technology:Asia Pacific Mammography Market Trends and Forecasts 2015-2019 2Lilly Sends Employees to Serve in Vulnerable Communities around the World 2Lilly Sends Employees to Serve in Vulnerable Communities around the World 3European Coagulation Testing Market Strategies 2015 2
... TARRYTOWN, N.Y., Feb. 28, 2011 Regeneron Pharmaceuticals, Inc. ... a second Phase 3 study (PRE-SURGE 2) in gout ... and all secondary study endpoints. The primary endpoint was ... 16-week treatment period. Patients who received ARCALYST at a ...
... MYL ) today announced that its subsidiary Matrix ... and Drug Administration (FDA) for its Abbreviated New Drug Application ... 400 mg, the generic version of Pfizer,s Neurontin ® ... Gabapentin Capsules had U.S. sales of approximately $300 ...
Cached Medicine Technology:ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 2ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 3ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 4ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 5ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 6ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 7ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 8ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 9ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 10
(Date:5/27/2015)... Throughout the past few months, Push to Walk has ... and reliability of the Shaw Gait Assessment in comparison to ... in the Department of Physical Therapy at Seton Hall University ... Gait Assessment is a free online tool, where the GaitRite ... considered the gold standard in providing information about how someone ...
(Date:5/27/2015)... StatRad, a leading provider of cloud-based medical ... Mr. Chris E. Hafey as its new Chief Technology ... of leading new development projects and has extensive experience ... served as the Chief Technology Officer for OnPoint Medical ... for Vital Images. , "I am very excited to ...
(Date:5/27/2015)... Khanna Vision Institute (KVI) announced the launch of a ... keratoconus eye disease . Keratoconus is commonly known as bulging ... the teenage years. It worsens over the next two decades ... of the eye is defective. It becomes thin and unable ... poor vision which cannot even be corrected with glasses. Finally ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 Continuing its ... of healthier patients in the community, SmartPractice® ... (formerly John C. Lincoln). SmartPractice Vice President of Human ... Shaw presented a $25,000 check to Paulla Miller, Sherry ... Breast Health & Research Center on April 30. The ...
(Date:5/27/2015)... Dr. Omar Ibrahimi, Dermatologist and Director ... has been selected as part of a controlled launch ... the only physician in Connecticut) to offer the new ... removal of submental fat (double chin). The procedure is ... surgery and minimal risks. Dr. Ibrahimi is an invited ...
Breaking Medicine News(10 mins):Health News:Push to Walk Partners with Seton Hall University for Study 2Health News:StatRad Introduces Mr. Chris E. Hafey as Chief Technology Officer, and the Release of its Advanced Pure HTML5 DICOM Image Uploader 2Health News:KVI announced the launch of The Keratoconus website focused on age based keratoconus treatment . 2Health News:SmartPractice Donates $25,000 to HonorHealth Breast Health and Research Center 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 3
... COLUMBUS, Ga., June 1 Aflac Incorporated,announced today that ... president and deputy chief financial officer. Susan R. Blanck ... Japan. Both promotions are,effective June 1, 2008., Durant ... comptroller of,Aflac Incorporated. He was with Aflac for 10 ...
... lost, son in 1994, volunteered for AIDS Action and raised more than $250,000 ... ... Today,s 23rd AIDS Walk Boston,attracted more than 20,000 participants -- the most ... runners,over last year, with 600 runners in The Larry Kessler 5K Run -- ...
... malignancies, study suggests , , SUNDAY, June 1 (HealthDay News) ... have value in helping to prevent lung cancer. , ... inhibitor on the U.S. market, may reduce levels of ... team presented its findings Sunday at the American Society ...
... patients on chemotherapy , , SUNDAY, June 1 (HealthDay News) ... effects of treatment for head and neck cancer patients ... acupuncture. , A new study found significant reductions in ... neck dissection in patients receiving acupuncture. , "Although further ...
... Adults who survived childhood Hodgkins Lymphoma should ... according to researchers from Wake Forest University Baptist ... annual meeting of the American Society of Clinical ... pediatric oncologist, said a 26-center study of 1,927 ...
... finds , , SATURDAY, May 31 (HealthDay News) -- ... survival in women with advanced breast cancer, new ... adding Avastin (bevacizumab) to the chemotherapy drug Taxol ... doubled progression-free survival. , Avastin is already approved ...
Cached Medicine News:Health News:Martin Durant Promoted to Executive Vice President and Deputy CFO; Sue Blanck Promoted to First Senior Vice President of Aflac Japan 2Health News:Martin Durant Promoted to Executive Vice President and Deputy CFO; Sue Blanck Promoted to First Senior Vice President of Aflac Japan 3Health News:23rd AIDS Walk Boston Draws Five-Year Record-Setting 20,000+ Participants, Doubles Runners to 600 and Raises $1.2 Million 2Health News:23rd AIDS Walk Boston Draws Five-Year Record-Setting 20,000+ Participants, Doubles Runners to 600 and Raises $1.2 Million 3Health News:Celebrex May Reduce Levels of Lung Cancer Biomarker 2Health News:Celebrex May Reduce Levels of Lung Cancer Biomarker 3Health News:Acupuncture Eases Side Effects of Head, Neck Cancer Treatments 2Health News:Acupuncture Eases Side Effects of Head, Neck Cancer Treatments 3Health News:Survivors of childhood Hodgkin's lymphoma at higher risk of future health problems 2Health News:Avastin Added to Chemo Helps Women With Advanced Cancer 2Health News:Avastin Added to Chemo Helps Women With Advanced Cancer 3
Microwell IRMA for the detection of Intact PTH...
... Suture™ PREMIUM SURGICLIP™ clip applier consists of an ... containing 15 or 20 titanium clips. , ... vessel or other tubular structure. As the handles ... is closed around the vessel or structure. As ...
... Auto Suture™ Powered LDS™ single use stapler ... within the cartridge jaw and a knife ... closed staples. , ,The Auto Suture™ ... staples have application in abdominal, gynecological, orthopedic, ...
The ALLPORT and ALLPORT LS Endoscopic Rotating Multiple Clip Appliers have application for use on tubular structures or vessels. The tissue being ligated should be consistent with the size of the cli...
Medicine Products: